Schinzel-Giedion syndrome

Schinzel-Giedion syndrome (SGS), also known as Schinzel-Giedion midface retraction syndrome, is a rare and severe congenital disorder characterized by distinctive facial features, multiple congenital anomalies, and profound developmental delay. The condition is caused by de novo gain-of-function mutations in the SETBP1 gene (SET binding protein 1) on chromosome 18q12.3. It affects multiple body systems including the skeletal system, urogenital system, central nervous system, and cardiovascular system. Key clinical features include severe midface retraction (a flattened or recessed middle portion of the face), a prominent forehead, wide-open fontanelles and sutures, short nose with upturned tip, and hypertrichosis (excessive hair growth). Skeletal abnormalities are prominent and include broad ribs, sclerotic skull base, and cortical thickening of long bones. Urogenital malformations such as hydronephrosis are very common. Affected individuals typically experience severe intellectual disability, seizures (often refractory epilepsy), and significant neurological impairment. Congenital heart defects may also be present. A notable association with neuroepithelial tumors, particularly sacrococcygeal teratomas and intracranial tumors, has been reported. The prognosis for Schinzel-Giedion syndrome is generally poor, with most affected children surviving only into early childhood, though some individuals have survived longer. There is currently no cure or disease-specific treatment. Management is supportive and symptomatic, focusing on seizure control with antiepileptic medications, management of hydronephrosis, nutritional support (often requiring tube feeding), and monitoring for tumor development. A multidisciplinary approach involving neurology, nephrology, cardiology, and developmental specialists is essential for optimizing care.

Common questions about Schinzel-Giedion syndrome